

PRESCRIBING, RECORDING, AND REPORTING PROTON-BEAM THERAPY

CONTENTS

ACKNOWLEDGMENTS	i
PREFACE	1
ABSTRACT	3
EXECUTIVE SUMMARY	5
1 INTRODUCTION	11
1.1 Principles of proton therapy	11
1.1.1 Physical characteristics	11
1.1.2 Biological effects	15
1.1.3 Clinical evaluations	15
1.2 History of proton therapy	16
1.3 Present status	17
2 RADIATION BIOLOGY CONSIDERATIONS	21
2.1 Introduction	21
2.2 Microdosimetry and linear energy transfer	21
2.3 Review of published proton RBE values	21
2.3.1 RBE values determined using <i>in vitro</i> and <i>in vivo</i> systems	23
2.3.2 RBE versus depth for 60–250 MeV beams	24
2.3.2.1 60–85 MeV	24
2.3.2.2 160–250 MeV	25
2.3.2.3 RBE on the declining distal edge of the SOBP	25
2.4 Use of a generic RBE value	26
2.5 Dose specification	27
2.5.1 The RBE-weighted absorbed dose (D_{RBE})	28
3 BEAM DELIVERY AND PROPERTIES	29
3.1 Proton-therapy facilities	29
3.2 The treatment-delivery system	29
3.2.1 The beam nozzle and snout	29
3.2.1.1 Passive beam-delivery techniques	29
3.2.1.2 Dynamic beam-delivery techniques	32
3.2.1.2.1 Wobbled beams	35
3.2.1.2.2 Repainting	35
3.2.2 Patient support and positioning	36
3.2.3 Special treatment techniques	36

PRESCRIBING, RECORDING, AND REPORTING PROTON-BEAM THERAPY

3.2.3.1	<i>Eye treatments</i>	36
3.2.3.2	<i>Stereotactic radiosurgery and stereotactic radiotherapy</i>	37
3.2.4	<i>Rotating gantries</i>	37
3.3	Accelerators	38
3.3.1	<i>Linear accelerators</i>	39
3.3.2	<i>Cyclotrons, isochronous cyclotrons, and synchrocyclotrons</i>	39
3.3.3	<i>Synchrotrons</i>	41
3.3.4	<i>Typical accelerator operating parameters</i>	42
3.4	The properties of proton beams	43
3.4.1	<i>Proton interactions with matter</i>	43
3.4.2	<i>Definition and specification of beam properties and beam parameters</i>	43
3.4.2.1	<i>Beam properties</i>	44
3.4.2.2	<i>Beam parameters</i>	44
3.5	Radiation quality	46
4	DOSIMETRY	49
4.1	General considerations	49
4.2	Reference dosimetry with a Faraday cup	50
4.3	Reference dosimetry with a calorimeter	54
4.4	Reference dosimetry with ionization chambers having ^{60}Co calibration coefficients	57
4.4.1	<i>ICRU proton dosimetry protocol (ICRU 59)</i>	57
4.4.1.1	<i>Physical quantities for ICRU 59</i>	58
4.4.2	<i>IAEA proton dosimetry code of practice (TRS 398)</i>	59
4.4.2.1	<i>Physical quantities for TRS 398</i>	61
4.4.3	<i>Considerations concerning dry and humid air</i>	62
4.4.4	<i>The value of w/E in air for proton beams</i>	64
4.4.4.1	<i>Definitions</i>	64
4.4.4.2	<i>Determination of the $w(E)$ value</i>	65
4.4.5	<i>Comparison of proton dosimetry protocols</i>	66
4.4.6	<i>Relation between absorbed dose to water and air-kerma calibration coefficients</i>	68
4.5	Reference dosimetry for scanned beams	69
4.6	Ionization-chamber dosimetry comparisons	69
4.7	Beam monitoring	70
4.7.1	<i>Ionization chambers</i>	71
4.7.2	<i>Position and dose uniformity</i>	72
4.7.3	<i>Considerations for scanned beams</i>	73
4.7.4	<i>Secondary-emission monitors</i>	73
4.7.5	<i>Range/energy measurements</i>	74
4.8	Relative dosimetry	74
4.8.1	<i>Phantom materials</i>	74
4.8.2	<i>Detectors for dose-distribution measurements</i>	75
4.8.2.1	<i>Single ionization chambers</i>	76
4.8.2.2	<i>Silicon diodes</i>	76
4.8.2.3	<i>Radiographic films</i>	77
4.8.2.4	<i>Alanine</i>	77
4.8.2.5	<i>Other detectors</i>	78
4.8.3	<i>Determination of dose distributions</i>	80
4.8.3.1	<i>Range and depth-dose characteristics</i>	80
4.8.3.2	<i>Beam profiles and penumbrae</i>	81
5	GEOMETRIC TERMS, AND DOSE AND DOSE–VOLUME DEFINITIONS	83
5.1	Anatomic volumes relating to the tumor	83

CONTENTS

5.1.1	<i>Gross tumor volume (GTV)</i>	83
5.1.2	<i>Clinical target volume (CTV)</i>	84
5.1.2.1	<i>The dose intention for the CTV</i>	84
5.1.3	<i>Internal target volume (ITV)</i>	85
5.1.4	<i>Planning target volume (PTV)</i>	85
5.1.4.1	<i>Margins for the different types of variations and uncertainties</i>	85
5.1.4.2	<i>Delineating the PTV</i>	86
5.1.4.3	<i>Multiple PTVs</i>	86
5.1.4.4	<i>Proton-specific issues regarding the PTV</i>	86
5.2	Anatomic volumes relating to unininvolved normal tissues and organs	87
5.2.1	<i>Organ at risk (OAR)</i>	87
5.2.2	<i>Planning organ at risk volume (PRV)</i>	87
5.2.3	<i>Remaining volume at risk (RVR)</i>	88
5.3	Generic geometric terms	88
5.3.1	<i>Volume of interest (VOI)</i>	88
5.3.2	<i>Target volume (TV)</i>	88
5.3.3	<i>Surface of interest (SOI)</i>	88
5.3.4	<i>Point of interest (POI)</i>	88
5.4	Nomenclature	89
5.4.1	<i>Multiple GTVs, CTVs, and PTVs</i>	89
5.4.1.1	<i>One GTV plus a surrounding volume intended to receive the same dose</i>	89
5.4.1.2	<i>One GTV plus a surrounding volume intended to receive a lower dose</i>	89
5.4.1.3	<i>No GTV</i>	89
5.4.1.4	<i>Two spatially separated GTVs</i>	90
5.4.1.5	<i>Two nested GTVs plus a region of possible microscopic disease</i>	90
5.4.1.6	<i>Reduced tumor dose in a region closely adjacent to an OAR</i>	91
5.4.2	<i>Multiple OARs and PRVs</i>	91
5.4.3	<i>Number of RVRs</i>	91
5.4.4	<i>Qualification of geometric terms</i>	91
5.4.4.1	<i>Tumor, nodal, or metastatic basis for a target volume</i>	91
5.5	Variation of geometry with time	91
5.6	Dose and dose-volume related definitions	92
5.6.1	<i>One-dimensional dose and dose-volume summarization</i>	92
5.6.1.1	<i>The volume receiving at least a specified dose (V_D)</i>	92
5.6.1.2	<i>The least dose received by a specified volume (D_V)</i>	93
5.6.1.3	<i>Other dose measures</i>	93
5.6.2	<i>Two-dimensional dose-volume summarization</i>	93
5.6.2.1	<i>Two-dimensional dose displays</i>	93
5.6.2.2	<i>Dose-volume histograms (DVH)</i>	93
5.6.2.3	<i>Dose-area histograms (DAH)</i>	93
5.6.3	<i>Prescribed dose</i>	93
5.6.3.1	<i>Prescribed dose for multiple PTVs</i>	94
5.6.3.2	<i>Prescribed dose for multiple treatment segments (segment dose)</i>	94
5.6.4	<i>Relative dose</i>	94
5.6.5	<i>Treated volume</i>	94
5.6.6	<i>Conformity index (CI)</i>	94
5.6.7	<i>Irradiated volume (at a specified dose)</i>	94
6	TREATMENT PLANNING	95
6.1	Introduction	95
6.2	What is different about planning proton-beam therapy?	95
6.2.1	<i>Heterogeneities</i>	95
6.2.2	<i>Beam-delivery techniques</i>	96

6.2.3	<i>Single beams</i>	96
6.2.3.1	<i>Inverse beam design</i>	96
6.2.3.2	<i>Selection of beam directions</i>	96
6.2.3.3	<i>The PTV</i>	96
6.2.3.4	<i>The proton RBE</i>	97
6.2.3.5	<i>The design of beam-modifying devices</i>	97
6.2.3.6	<i>Repainting</i>	97
6.2.3.7	<i>Dose algorithms</i>	97
6.2.4	<i>Plans</i>	97
6.2.4.1	<i>Number of beams</i>	97
6.2.4.2	<i>Intensity-modulated proton therapy (IMPT)</i>	98
6.2.4.3	<i>Imaging</i>	98
6.2.4.4	<i>Positioning accuracy, immobilization, and localization</i>	98
6.2.4.5	<i>Uncertainty analysis</i>	98
6.2.4.6	<i>Target volume size</i>	99
6.2.5	<i>Quality assurance</i>	99
6.3	The patient's anatomy	99
6.4	Heterogeneities	100
6.4.1	<i>Introduction</i>	100
6.4.2	<i>Interactions of protons in matter</i>	100
6.4.2.1	<i>Mass thickness</i>	100
6.4.2.2	<i>Energy loss</i>	100
6.4.2.2.1	<i>Water-equivalent density</i>	100
6.4.2.3	<i>Multiple Coulomb scattering</i>	101
6.4.3	<i>Bulk heterogeneity intersecting the full beam</i>	101
6.4.4	<i>Bulk heterogeneity partially intersecting the beam</i>	102
6.4.5	<i>Complexly structured heterogeneities</i>	102
6.4.6	<i>Compensation for heterogeneities</i>	103
6.4.6.1	<i>Conversion from CT Hounsfield number to water-equivalent density</i>	103
6.4.6.1.1	<i>Direct-fit method</i>	104
6.4.6.1.2	<i>Stoichiometric method</i>	104
6.4.6.1.3	<i>Confirmation of calibration</i>	104
6.4.6.1.4	<i>Accuracy</i>	105
6.4.6.2	<i>Design of compensators</i>	105
6.4.6.2.1	<i>Choice of range</i>	106
6.4.6.2.2	<i>Compensator design close to, and outside, the projected target boundary</i>	106
6.4.6.2.3	<i>Real and virtual compensators</i>	107
6.4.6.2.4	<i>The effect of an air gap between compensator and patient</i>	107
6.4.6.2.5	<i>High-Z heterogeneities</i>	107
6.5	Design of individual proton beams	108
6.5.1	<i>Compensation for heterogeneities</i>	108
6.5.1.1	<i>Choosing beam directions</i>	108
6.5.1.2	<i>Tangential irradiation</i>	108
6.5.2	<i>Categories of models for dose computation</i>	108
6.5.2.1	<i>Uniform-intensity beam algorithms</i>	109
6.5.2.2	<i>Pencil-beam algorithms</i>	109
6.5.2.3	<i>Monte Carlo algorithms</i>	109
6.5.3	<i>Normalization and the calculation of monitor units</i>	110
6.6	Design of groups of beams: the treatment plan	110
6.6.1	<i>Treatment goals and constraints</i>	110
6.6.1.1	<i>Setting goal(s) and constraints</i>	110
6.6.1.2	<i>Establishing a score combining target-volume and normal-tissue effects</i>	110

CONTENTS

6.6.1.3	<i>Target-volume goals and constraints</i>	111
6.6.1.4	<i>Normal-tissue constraints</i>	111
6.6.2	<i>Approaches to treatment design</i>	111
6.6.2.1	<i>Uniform-intensity radiation therapy</i>	111
6.6.2.2	<i>Intensity-modulated radiation therapy (IMRT)</i>	112
6.7	Plan assessment	112
6.7.1	<i>Inspection of the dose distribution</i>	112
6.7.2	<i>Clinical feasibility</i>	113
6.7.3	<i>Dose-summarizing quantities</i>	113
6.8	Plan comparison	113
6.8.1	<i>Plan comparison by inspection</i>	114
6.8.2	<i>Automated plan comparison</i>	114
6.9	Plan optimization	115
6.10	Comparison of uniform-intensity versus IMPT treatment plans	115
6.11	Special techniques	118
6.11.1	<i>Intraocular treatments with protons</i>	118
6.11.1.1	<i>Model of the patient anatomy</i>	118
6.11.1.2	<i>Beam simulation</i>	118
6.11.1.3	<i>Output of the planning process</i>	118
6.11.1.4	<i>Presentation of results</i>	118
6.11.1.5	<i>Treatment example</i>	118
6.11.2	<i>Stereotactic treatments with protons</i>	119
6.11.2.1	<i>Immobilization</i>	119
6.11.2.2	<i>Imaging</i>	121
6.11.2.3	<i>Planning</i>	121
6.11.2.4	<i>Treatment</i>	122
7	MOTION MANAGEMENT	123
7.1	Motion of, and within, the patient	123
7.2	Support and immobilization	123
7.2.1	<i>Proton-specific aspects of immobilization</i>	123
7.2.2	<i>Immobilization techniques</i>	124
7.3	Localization	124
7.3.1	<i>Localization based on skin marks</i>	124
7.3.2	<i>Localization based on bony anatomy</i>	124
7.3.3	<i>Localization relative to the immobilization device</i>	125
7.3.4	<i>Localization based on identification of target-volume markers or the tumor itself</i>	125
7.4	Verification	125
7.4.1	<i>Verification using radiography</i>	125
7.4.2	<i>Verification using positron emission tomography</i>	125
7.5	Organ motion	126
7.5.1	<i>The measurement of organ motion</i>	126
7.5.2	<i>Organ motion in the absence of special measures</i>	126
7.5.3	<i>Organ motion under conditions of respiration gating</i>	126
7.5.4	<i>Organ motion with tumor tracking</i>	127
7.6	Compensation for patient and organ motion	127
7.6.1	<i>Margins at the periphery of the CTV or OARs: lateral margins</i>	127
7.6.2	<i>Margins at the periphery of the CTV or OARs: margin in depth</i>	128
7.6.3	<i>Dose variation within the CTV and OARs: interplay effects</i>	128
7.6.3.1	<i>Experimental observation of interplay effects</i>	129
7.6.3.2	<i>Repainting to reduce the influence of interplay effects</i>	130
7.7	Conclusion	130

8 ESTIMATION AND PRESENTATION OF UNCERTAINTY IN THE DELIVERED DOSE	131
8.1 The inevitability of uncertainty	131
8.2 The estimation of uncertainty	131
8.3 The presentation of uncertainty	132
8.4 Recommendations for the consideration and reporting of uncertainty	134
9 QUALITY ASSURANCE	135
9.1 Proton beam-delivery systems	135
9.2 Patient positioning and immobilization	137
9.3 Treatment-planning systems	137
9.4 Examples of periodic checks	139
10 PRESCRIBING, RECORDING, AND REPORTING TREATMENT	141
10.1 Introduction	141
10.2 General recommendations for prescribing, recording, and reporting	141
10.2.1 The components of prescribing, recording, and reporting a patient's treatment	141
10.2.2 Planning aims	141
10.2.2.1 Specifying planning aims	141
10.2.2.2 Normal-tissue constraints	142
10.2.2.3 Selection of treatment approach: the treatment plan	143
10.2.3 Prescribing proton-beam therapy	143
10.3.1 General approaches to prescribing	143
10.3.2 The prescription	143
10.3.3 General recommendations for prescribing	143
10.3.4 Approval of the prescription and technical data	143
10.2.4 Additional aspects of prescribing, recording, and reporting	149
10.4.1 Therapy equipment	149
10.4.2 Beam-shaping techniques	149
10.4.3 Techniques for dealing with heterogeneities	149
10.4.4 Margins	149
10.2.5 Recording proton-beam therapy	149
10.5.1 The treatment record	149
10.5.2 The patient's record	149
10.2.6 Reporting the treatment of a single patient	149
10.6.1 Reporting proton-beam therapy	149
10.6.2 Patient-specific reports	150
10.6.2.1 The initial medical note	150
10.6.2.2 The completion note	150
10.6.2.3 Summary report to the referring physician	150
10.6.2.4 Case report	150
10.6.2.5 Detailed report to a physician	150
10.2.7 Reporting proton-beam therapy for a series of patients	150
APPENDIX A IMPLEMENTATION OF THE TRS 398 CODE OF PRACTICE FOR IONIZATION CHAMBER DOSIMETRY	151
A.1 Calibration of ionization chambers	151
A.1.1 Calibration in a ^{60}Co beam	151
A.2 Reference dosimetry in the user proton beam	153
A.2.1 Determination of the absorbed dose to water	153
A.2.2 Practical considerations for measurements in the proton beam	153
A.2.3 Corrections for influence quantities	153

CONTENTS

A.2.3.1 <i>Temperature, pressure, and humidity</i>	153
A.2.3.2 <i>Electrometer calibration</i>	154
A.2.3.3 <i>Polarity effect</i>	154
A.2.3.4 <i>Ion recombination</i>	154
A.3 Dosimetry worksheet (IAEA, 2000)	157
APPENDIX B CLINICAL EXAMPLES	159
Case number B.1 Uveal melanoma	160
<i>General patient information</i>	160
<i>Medical evaluation of presenting lesion</i>	160
<i>General medical evaluation</i>	160
<i>Treatment intent</i>	160
<i>Treatment planning</i>	161
<i>Patient immobilization and positioning</i>	161
<i>Treatment prescription</i>	161
<i>Treatment technique</i>	162
<i>Quality assurance</i>	162
<i>Equipment</i>	162
<i>Total doses delivered</i>	163
<i>Patient status at completion of treatment</i>	163
<i>Addendum: technical information</i>	163
Case number B.2 Adenocarcinoma of prostate	164
<i>General patient information</i>	164
<i>Medical evaluation of presenting lesion</i>	164
<i>General medical evaluation</i>	164
<i>Treatment intent</i>	164
<i>Treatment planning</i>	164
<i>Patient immobilization and positioning</i>	164
<i>Treatment prescription</i>	165
<i>Treatment technique</i>	165
<i>Quality assurance</i>	165
<i>Equipment</i>	165
<i>Total doses delivered</i>	166
<i>Patient status at completion of treatment</i>	167
<i>Addendum: technical information</i>	167
Case number B.3 Carcinoma of lung	168
<i>General patient information</i>	168
<i>Medical evaluation of presenting lesion</i>	168
<i>General medical evaluation</i>	168
<i>Treatment intent</i>	168
<i>Treatment planning</i>	168
<i>Patient immobilization and positioning</i>	169
<i>Treatment prescription</i>	169
<i>Treatment technique</i>	169
<i>Quality assurance</i>	170
<i>Equipment</i>	171
<i>Total doses delivered</i>	171
<i>Patient status at completion of treatment</i>	171
<i>Addendum: technical information</i>	171
Case number B.4 Acoustic neuroma	172
<i>General patient information</i>	172
<i>Medical evaluation of presenting lesion</i>	172
<i>General medical evaluation</i>	172
<i>Treatment intent</i>	172

PRESCRIBING, RECORDING, AND REPORTING PROTON-BEAM THERAPY

<i>Treatment planning</i>	172
<i>Patient immobilization and positioning</i>	174
<i>Treatment prescription</i>	174
<i>Treatment technique</i>	175
<i>Quality assurance</i>	175
<i>Equipment</i>	175
<i>Total doses delivered</i>	175
<i>Patient status at completion of treatment</i>	175
<i>Addendum: technical information</i>	176
Case number B.5 Medulloblastoma (pediatric)	177
<i>General patient information</i>	177
<i>Medical evaluation of presenting lesion</i>	177
<i>General medical evaluation</i>	177
<i>Treatment intent</i>	177
<i>Treatment planning</i>	177
<i>Patient immobilization and positioning</i>	178
<i>Treatment prescription</i>	179
<i>Treatment technique</i>	181
<i>Quality assurance</i>	181
<i>Equipment</i>	181
<i>Total doses delivered</i>	181
<i>Patient status at completion of treatment</i>	182
<i>Addendum: technical information</i>	183
Case number B.6 Skull-base chordoma	185
<i>General patient information</i>	185
<i>Medical evaluation of presenting lesion</i>	185
<i>General medical evaluation</i>	185
<i>Treatment intent</i>	185
<i>Treatment planning</i>	185
<i>Patient immobilization and positioning</i>	186
<i>Treatment prescription</i>	186
<i>Treatment technique</i>	186
<i>Quality assurance</i>	186
<i>Equipment</i>	186
<i>Total doses delivered</i>	187
<i>Patient status at completion of treatment</i>	188
<i>Addendum: technical information</i>	188
REFERENCES	189